CureVac to Present at the 12th International mRNA Health Conference
CureVac (Nasdaq: CVAC) announced upcoming presentations at the 12th International mRNA Health Conference in Boston, November 12-14, 2024. The company will share two oral presentations and four posters, featuring expanded data from their Phase 1 CVGBM cancer vaccine study in glioblastoma patients. Initial results showed 77% of evaluable patients developed cancer antigen-specific T-cell responses, with 84% of immune responses being vaccine-generated.
The presentations will include detailed safety and immunogenicity data from the dose escalation study, along with CureVac's approach to optimizing LNP delivery. Additional posters will showcase the company's mRNA platform optimization strategies and new development targets in oncology and infectious disease areas.
CureVac (Nasdaq: CVAC) ha annunciato le presentazioni in programma per la 12ª Conferenza Internazionale sulla Salute dell'mRNA a Boston, dal 12 al 14 novembre 2024. L'azienda condividerà due presentazioni orali e quattro poster, con dati ampliati sullo studio del vaccino contro il cancro CVGBM in pazienti affetti da glioblastoma. I risultati iniziali hanno mostrato che il 77% dei pazienti valutabili ha sviluppato risposte T-cellulari specifiche per l'antigene tumorale, con l'84% delle risposte immunitarie generate dal vaccino.
Le presentazioni includeranno dati dettagliati sulla sicurezza e sull'immunogenicità dallo studio di escalation della dose, insieme all'approccio di CureVac per ottimizzare la somministrazione LNP. Poster aggiuntivi mostreranno le strategie di ottimizzazione della piattaforma mRNA dell'azienda e i nuovi obiettivi di sviluppo nei settori dell'oncologia e delle malattie infettive.
CureVac (Nasdaq: CVAC) anunció las presentaciones que se llevarán a cabo en la 12ª Conferencia Internacional de Salud de mRNA en Boston, del 12 al 14 de noviembre de 2024. La empresa compartirá dos presentaciones orales y cuatro carteles, con datos ampliados de su estudio de la vacuna contra el cáncer CVGBM en pacientes con glioblastoma. Los resultados iniciales mostraron que el 77% de los pacientes evaluables desarrollaron respuestas de células T específicas para el antígeno del cáncer, con el 84% de las respuestas inmunitarias generadas por la vacuna.
Las presentaciones incluirán datos detallados sobre la seguridad y la inmunogenicidad del estudio de escalada de dosis, junto con el enfoque de CureVac para optimizar la entrega de LNP. Carteles adicionales mostrarán las estrategias de optimización de la plataforma de mRNA de la empresa y nuevos objetivos de desarrollo en las áreas de oncología y enfermedades infecciosas.
CureVac (Nasdaq: CVAC)는 2024년 11월 12일부터 14일까지 보스턴에서 열리는 제12회 국제 mRNA 건강 회의에서 발표할 예정이라고 발표했습니다. 이 회사는 교모세포종 환자에 대한 CVGBM 암 백신 연구에서 확대된 데이터가 포함된 두 개의 구두 발표와 네 개의 포스터를 공유할 것입니다. 초기 결과에 따르면 평가 가능 환자의 77%가 암 항원 특이 T세포 반응을 개발했습니다, 면역 반응 중 84%가 백신에 의해 생성되었습니다.
발표 내용에는 용량 증가 연구에서의 상세한 안전성 및 면역원성 데이터와 함께 LNP 전달 최적화에 대한 CureVac의 접근 방법이 포함될 예정입니다. 추가 포스터에서는 회사의 mRNA 플랫폼 최적화 전략과 종양학 및 감염병 분야의 새로운 개발 목표를 보여줄 것입니다.
CureVac (Nasdaq: CVAC) a annoncé des présentations à venir lors de la 12e Conférence Internationale sur la Santé de l'mRNA à Boston, du 12 au 14 novembre 2024. L'entreprise présentera deux présentations orales et quatre affiches, mettant en avant des données élargies de leur étude de vaccin contre le cancer CVGBM chez des patients atteints de glioblastome. Les résultats initiaux ont montré que 77 % des patients évaluables ont développé des réponses T-cellulaires spécifiques à l'antigène tumoral, avec 84 % des réponses immunitaires générées par le vaccin.
Les présentations incluront des données détaillées sur la sécurité et l'immunogénicité de l'étude d'escalade de dose, ainsi que l'approche de CureVac pour optimiser la délivrance de LNP. Des affiches supplémentaires présenteront les stratégies d'optimisation de la plateforme mRNA de l'entreprise et de nouveaux objectifs de développement dans les domaines de l'oncologie et des maladies infectieuses.
CureVac (Nasdaq: CVAC) gab bekannt, dass bevorstehende Präsentationen auf der 12. Internationalen mRNA Gesundheitskonferenz in Boston vom 12. bis 14. November 2024 stattfinden werden. Das Unternehmen wird zwei mündliche Präsentationen und vier Poster teilen, die erweiterte Daten aus ihrer Phase-1-Studie zu dem CVGBM-Krebsimpfstoff bei Glioblastom-Patienten zeigen. Die ersten Ergebnisse zeigten, dass 77% der bewertbaren Patienten krebsantigen-spezifische T-Zell-Antworten entwickelten, wobei 84% der Immunantworten impfstoffbedingt waren.
Die Präsentationen werden detaillierte Sicherheits- und Immunogenitätsdaten aus der Dosissteigerungsstudie enthalten, sowie CureVacs Ansatz zur Optimierung der LNP-Verabreichung. Weitere Poster werden die Optimierungsstrategien der mRNA-Plattform des Unternehmens und neue Entwicklungsziele in den Bereichen Onkologie und Infektionskrankheiten präsentieren.
- None.
- None.
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA Health Conference, taking place in Boston, Massachusetts, November 12-14, 2024.
More detailed preliminary safety, tolerability and immunogenicity data from the dose escalation part of CureVac's ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be shared in an oral presentation. Initial data from this study was presented last month at the European Society for Medical Oncology (ESMO) Congress demonstrating that treatment with CVGBM monotherapy successfully induced cancer antigen-specific T-cell responses in
A second oral presentation will cover CureVac's approach to developing optimized LNP delivery, while posters shared at the meeting will provide additional data on how CureVac optimizes its mRNA platform with different approaches as well as highlighting new targets for future development programs. The data to be shared will demonstrate the potential of CureVac's mRNA platform in technology optimization, oncology, and infectious disease, driving future innovation in the mRNA space.
"With our recent corporate realignment and increased focus on research and innovation to develop meaningful mRNA medicines in different therapeutic areas, CureVac is more committed than ever to extending the horizons of mRNA. We are pleased to be presenting the recently announced promising clinical data from our glioblastoma mRNA vaccine program as well as results from our ongoing research in lipid nanoparticle delivery technology, oncology and infectious diseases," said Dr. Myriam Mendila, Chief Scientific Officer at CureVac. "These presentations demonstrate the evolution of our long-standing commitment to apply mRNA technology in service to patients across a diverse spectrum of disease areas."
Details on the two oral presentations are below:
Title: Development of multiepitope mRNA vaccines - first results of Phase I human study in Glioblastoma patients
Session type: Oral Presentation
Date: Thursday, November 14
Time: 1:44 p.m. EST
Presenting Author: Regina Heidenreich, Ph.D., Senior Director Oncology Preclinical Development, CureVac SE
Title: Development and optimization of lipid nanoparticles for delivery of mRNA vaccines
Session type: Oral Presentation
Date: Thursday, November 14
Time: 9:38 a.m. EST
Presenting Author: Paula Muresan, Ph.D., Research Scientist, CureVac SE
For more information on the conference and program, please visit the website: https://www.mrna-conference.com/
About CureVac
CureVac (Nasdaq:CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.
CureVac Media and Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
Forward-Looking Statements of CureVac
This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway expectations, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (the "SEC"). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
SOURCE: CureVac
View the original press release on accesswire.com
FAQ
What are the key findings from CureVac's CVGBM cancer vaccine study presented at ESMO?
When and where will CureVac (CVAC) present their mRNA research in November 2024?
What topics will CureVac's (CVAC) oral presentations cover at the mRNA Health Conference?
When are CureVac's (CVAC) scheduled presentation times at the mRNA Conference?
